Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISOPHROL vs ALAVERT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.
Relief of symptoms of seasonal or perennial allergic rhinitis,Relief of symptoms of vasomotor rhinitis,Relief of nasal congestion associated with the common cold,Relief of sinusitis symptoms
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Terminal elimination half-life of loratadine is 8–11 hours; its active metabolite desloratadine has a half-life of 17–24 hours. The longer half-life of desloratadine contributes to sustained antihistaminic effect.
Dexbrompheniramine is metabolized in the liver primarily via CYP450 enzymes; pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine.
Primarily metabolized by CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Approximately 40% of the dose is excreted in urine (25% as unchanged drug and 15% as active metabolite desloratadine) and 40% in feces (as metabolites).
Approximately 50-60% bound to plasma proteins, primarily albumin.
Loratadine: 97–99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound.
Volume of distribution is approximately 1.5-2.5 L/kg, indicating extensive tissue distribution.
Loratadine: approximately 120 L (1.7 L/kg for a 70 kg adult), indicating extensive tissue distribution. Desloratadine: 30–40 L/kg.
Oral bioavailability is about 70-80% due to first-pass metabolism.
Oral bioavailability is low (approximately 40–50%) due to extensive first-pass metabolism. Food increases bioavailability by 40% but does not affect clinical efficacy.
GFR 30-50 m L/min: administer every 6-8 hours. GFR 15-29 m L/min: administer every 12 hours. GFR <15 m L/min: not recommended.
For GFR 30-50 m L/min: 10 mg every 48 hours. For GFR <30 m L/min or on dialysis: avoid use or adjust to 10 mg every 72 hours with close monitoring.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution, reduce dose frequency. Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 10 mg every 48 hours. Child-Pugh C: avoid use or 10 mg every 72 hours.
Children 6-11 years: 1/2 tablet (3 mg dexbrompheniramine / 30 mg pseudoephedrine) orally every 4-6 hours, max 2 tablets per day. Children <6 years: not recommended.
Age 6-11 years: 5 mg orally once daily; for PRN use, 5 mg every 4-6 hours, max 15 mg/day. Age ≥12 years: 10 mg orally once daily or 10 mg every 4-6 hours PRN, max 24 mg/day.
Initiate with 1/2 tablet every 6-8 hours; monitor for anticholinergic effects and hypertension; avoid in patients >65 years due to increased risk of adverse effects.
Initiate at 5 mg orally once daily; may increase to 10 mg once daily if tolerated and needed. Caution due to increased risk of anticholinergic effects and impaired renal function.
None.
None.
Cardiovascular effects: may cause hypertension, palpitations, arrhythmias,Central nervous system stimulation: may cause insomnia, dizziness, tremor,Urinary retention: use with caution in patients with BPH or urinary obstruction,Increased intraocular pressure: avoid in narrow-angle glaucoma,Elderly patients: more sensitive to anticholinergic and cardiovascular effects
Avoid use in patients with severe hepatic impairment,Renal impairment may require dose adjustment,Caution in elderly patients due to increased anticholinergic sensitivity
Severe hypertension,Coronary artery disease,Concurrent use of MAO inhibitors or within 14 days of such therapy,Narrow-angle glaucoma,Urinary retention,Severe renal impairment,Hypersensitivity to any component
Hypersensitivity to loratadine or any component of the formulation
Avoid consuming alcohol while taking Disophrol. Caffeine may increase restlessness and insomnia. There is no specific food interaction, but taking with food may reduce gastrointestinal upset.
Grapefruit juice may slightly increase loratadine absorption but not clinically significant. No specific dietary restrictions. Alcohol may increase CNS depression.
DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis with antihistamine use, but data are limited; pseudoephedrine may be associated with a small risk of gastroschisis and hemifacial microsomia. Second and third trimesters: No specific fetal risks have been clearly established; pseudoephedrine may cause fetal tachycardia and decreased uterine blood flow at high doses. Avoid in third trimester due to potential for uterine contraction inhibition and neonatal respiratory depression from antihistamines.
ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on available human data, first trimester exposure does not show increased risk of major malformations. Second and third trimester risks are not established, but adverse fetal outcomes are unlikely given lack of placental transfer concerns.
DISOPHROL is excreted into breast milk. Dexchlorpheniramine: Present in low levels, M/P ratio not established; may cause irritability and drowsiness in infants. Pseudoephedrine: Excreted into breast milk with M/P ratio of approximately 2.6-3.5; may cause infant irritability and decreased milk production. Use caution and monitor infant for excessive drowsiness or irritability.
Loratadine is excreted into human breast milk. The milk-to-plasma ratio is approximately 1.17, with low relative infant dose (<2% of maternal weight-adjusted dose). Considered compatible with breastfeeding, but monitor infant for drowsiness or irritability. Caution in premature infants or those with renal impairment.
No specific dose adjustments are recommended in pregnancy; however, use lowest effective dose and shortest duration. Due to increased plasma volume and renal clearance in pregnancy, pseudoephedrine may have reduced efficacy; dose may need empirical adjustment based on response. Avoid extended-release formulations in pregnancy.
No dose adjustment is routinely recommended for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, hepatic metabolism) are not significant enough to require dose changes for loratadine. Standard adult dose (10 mg once daily) can be used.
Disophrol combines an antihistamine (dexbrompheniramine) and a decongestant (pseudoephedrine). Avoid in patients with hypertension, coronary artery disease, or hyperthyroidism due to pseudoephedrine's sympathomimetic effects. Monitor for anticholinergic side effects (drowsiness, dry mouth) from the antihistamine component. Use with caution in glaucoma, urinary retention, and prostatic hypertrophy.
Alavert (loratadine) is a non-sedating antihistamine with minimal anticholinergic effects. Onset of action is within 1-3 hours; peak effect at 8-12 hours. Useful for chronic urticaria and allergic rhinitis. Does not cause significant QTc prolongation. Avoid in severe hepatic impairment (Child-Pugh C) without dose adjustment.
Take this medication as prescribed; do not exceed recommended dose due to risk of serious side effects.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Do not take with other medications containing decongestants or antihistamines.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or difficulty urinating.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.
Take once daily at the same time, with or without food.,Do not exceed recommended dose to avoid side effects.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not use for acute asthma attacks or lower respiratory symptoms.,Store at room temperature away from moisture and heat.,Notify your doctor if symptoms persist or worsen.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISOPHROL vs ALAVERT, answered by our medical review team.
DISOPHROL is a Antihistamine/Decongestant Combination that works by Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.. ALAVERT is a Second-generation Antihistamine that works by Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISOPHROL and ALAVERT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISOPHROL is: 1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.. The standard adult dose of ALAVERT is: 10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISOPHROL and ALAVERT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISOPHROL is classified as Category C. DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis wi. ALAVERT is classified as Category C. ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on ava. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.